Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Frederieke H. van Duijnhoven"'
Autor:
Yuan Gao, Sofia Ventura-Diaz, Xin Wang, Muzhen He, Zeyan Xu, Arlene Weir, Hong-Yu Zhou, Tianyu Zhang, Frederieke H. van Duijnhoven, Luyi Han, Xiaomei Li, Anna D’Angelo, Valentina Longo, Zaiyi Liu, Jonas Teuwen, Marleen Kok, Regina Beets-Tan, Hugo M. Horlings, Tao Tan, Ritse Mann
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Multi-modal image analysis using deep learning (DL) lays the foundation for neoadjuvant treatment (NAT) response monitoring. However, existing methods prioritize extracting multi-modal features to enhance predictive performance, with limited
Externí odkaz:
https://doaj.org/article/c0d62ff4a3f64984a6d212ffdc266b26
Autor:
Josefien P. van Olmen, Veerle CM. Geurts, Marie-Jeanne TFD. Vrancken Peeters, Caroline A. Drukker, Marcel PM. Stokkel, Marleen Kok, Frederieke H. van Duijnhoven
Publikováno v:
Breast, Vol 78, Iss , Pp 103822- (2024)
Background: Guidelines recommend systemic therapy for stage I HER2+ breast cancer (BC). Neoadjuvant systemic treatment (NAST) allows response-guided adjuvant treatment. However, prior to NAST only clinical nodal staging is available, risking undertre
Externí odkaz:
https://doaj.org/article/c83b28677bb04a91a21da8b4b91658e4
Autor:
Sena Alaeikhanehshir, Madelon M. Voets, Frederieke H. van Duijnhoven, Esther H. lips, Emma J. Groen, Marja C. J. van Oirsouw, Shelley E. Hwang, Joseph Y. Lo, Jelle Wesseling, Ritse M. Mann, Jonas Teuwen, Grand Challenge PRECISION Consortium Steering Group
Publikováno v:
Cancer Imaging, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Ductal Carcinoma In Situ (DCIS) can progress to invasive breast cancer, but most DCIS lesions never will. Therefore, four clinical trials (COMET, LORIS, LORETTA, AND LORD) test whether active surveillance for women with low-risk D
Externí odkaz:
https://doaj.org/article/fc3bee61c9014d9a860d6d7699fca1a8
Autor:
Josefien P. van Olmen, Chaja F. Jacobs, Sanne A.L. Bartels, Claudette E. Loo, Joyce Sanders, Marie-Jeanne T.F.D. Vrancken Peeters, Caroline A. Drukker, Frederieke H. van Duijnhoven, Marleen Kok
Publikováno v:
Breast, Vol 75, Iss , Pp 103726- (2024)
Objective: This study aims to evaluate the response to and surgical benefits of neoadjuvant endocrine therapy (NET) in ER+/HER2-breast cancer patients who are clinically high risk, but genomic low risk according to the 70-gene signature (MammaPrint).
Externí odkaz:
https://doaj.org/article/704ad2649c1245a2bc5b540ca828061f
Publikováno v:
Breast, Vol 71, Iss , Pp 89-95 (2023)
The increasing use and effectiveness of primary systemic treatment (PST) enables tailored locoregional treatment. About one third of clinically node positive (cN+) breast cancer patients achieve pathologic complete response (pCR) of the axilla, with
Externí odkaz:
https://doaj.org/article/01eca1f60ed542ae9a36b20aef659ad4
Autor:
Ariane A. van Loevezijn, Marcel P. M. Stokkel, Maarten L. Donswijk, Erik D. van Werkhoven, Marieke E. M. van der Noordaa, Frederieke H. van Duijnhoven, Marie-Jeanne T. F. D. Vrancken Peeters
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Purpose Axillary staging before neoadjuvant systemic therapy in clinically node-positive breast cancer patients with tailored axillary treatment according to the Marking Axillary lymph nodes with radioactive iodine seeds (MARI)-protocol, a p
Externí odkaz:
https://doaj.org/article/6a968ec94da8444d97029fdfe941649c
Autor:
Jacqueline A. ter Stege, Hester S.A. Oldenburg, Leonie A.E. Woerdeman, Arjen J. Witkamp, Jacobien M. Kieffer, Martine A. van Huizum, Frederieke H. van Duijnhoven, Daniela E.E. Hahn, Miranda A. Gerritsma, Marianne A. Kuenen, Nikola (A.N.) Kimmings, Quinten (P.Q.) Ruhé, Irene S. Krabbe-Timmerman, Martijne van’t Riet, Eveline M.L. Corten, Kerry A. Sherman, Eveline M.A. Bleiker
Publikováno v:
Breast, Vol 55, Iss , Pp 91-97 (2021)
Background: Breast cancer (BC) patients who are treated with mastectomy are frequently offered immediate breast reconstruction. This study aimed to assess decisional conflict in patients considering immediate breast reconstruction, and to identify fa
Externí odkaz:
https://doaj.org/article/118f3d1e34954e07b48c151af8b4a76a
Autor:
Sena Alaeikhanehshir, Ellen G. Engelhardt, Frederieke H. van Duijnhoven, Maartje van Seijen, Patrick A. Bhairosing, Donna Pinto, Deborah Collyar, Elinor Sawyer, Shelley E. Hwang, Alastair M. Thompson, Jelle Wesseling, Esther H. Lips, Marjanka K. Schmidt
Publikováno v:
Breast, Vol 50, Iss , Pp 95-103 (2020)
Objective: The majority of ‘low-risk’ (grade I/II) Ductal Carcinoma In Situ (DCIS) may not progress to invasive breast cancer during a women’s lifetime. Therefore, the safety of active surveillance versus standard surgical treatment for DCIS is
Externí odkaz:
https://doaj.org/article/b800c69886634c58ac9c9fedd17ea552
Autor:
Jacqueline A. ter Stege, Leonie A. E. Woerdeman, Daniela E. E. Hahn, Martine A. van Huizum, Frederieke H. van Duijnhoven, Jacobien M. Kieffer, Valesca P. Retèl, Kerry A. Sherman, Arjen J. Witkamp, Hester S. A. Oldenburg, Eveline M. A. Bleiker
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 19, Iss 1, Pp 1-12 (2019)
Abstract Background Most breast cancer patients undergoing mastectomy are candidates for breast reconstruction. Deciding about breast reconstruction is complex and the preference-sensitive nature of this decision requires an approach of shared decisi
Externí odkaz:
https://doaj.org/article/e536d0e7fb0c4298aad7dd0128640520
Autor:
Annemiek K. E. van Hemert, Josefien P. van Olmen, Liesbeth J. Boersma, John H. Maduro, Nicola S. Russell, Jolien Tol, Ellen G. Engelhardt, Emiel J. Th. Rutgers, Marie-Jeanne T. F. D. Vrancken Peeters, Frederieke H. van Duijnhoven
Publikováno v:
Breast Cancer Research and Treatment, 199(1), 81-89. SPRINGER
Breast Cancer Research and Treatment, 199, 81-89. Springer, Cham
Breast Cancer Research and Treatment, 199, 81-89. Springer, Cham
Purpose: Neoadjuvant systemic therapy (NST) is increasingly used in breast cancer patients and depending on subtype, 10–89% of patients will attain pathologic complete response (pCR). In patients with pCR, risk of local recurrence (LR) after breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5759714b89fcb7a1feba2ec10948ea43
https://research.rug.nl/en/publications/c899ec1c-7e92-4b22-86c3-18ca97cce660
https://research.rug.nl/en/publications/c899ec1c-7e92-4b22-86c3-18ca97cce660